0.787
Plus Therapeutics Inc Aktie (PSTV) Neueste Nachrichten
Plus Therapeutics (NASDAQ:PSTV) Price Target Raised to $20.00 at Ascendiant Capital Markets - Defense World
Short Interest in Plus Therapeutics, Inc. (NASDAQ:PSTV) Rises By 34.5% - Defense World
Plus Therapeutics Appoints Kyle Guse to Board - MSN
Plus Therapeutics reports progress in CNS cancer treatment By Investing.com - Investing.com Canada
Plus Therapeutics Inc (NASDAQ: PSTV) Analysts Expect It Could Climb 89.63% From Current Levels. - stocksregister.com
Plus Therapeutics Presents New Data Highlighting Clinical Benefi - GuruFocus
Plus Therapeutics (PSTV) Unveils Promising Data on REYOBIQ at Upcoming Conference | PSTV Stock News - GuruFocus
Plus Therapeutics reports progress in CNS cancer treatment - Investing.com
Plus Therapeutics Presents New Data Highlighting Clinical - GlobeNewswire
New Cancer Drug REYOBIQ Achieves Breakthrough 86% Clinical Benefit in Brain Metastases Study - Stock Titan
Plus Therapeutics (PSTV) Plans Massive Stock Sale - GuruFocus
Plus Therapeutics Inc (PSTV) Volatility Hits 17.12% – Here Is What You Should Do - Stocksregister
Promising Outlook for Plus Therapeutics: Buy Rating Affirmed Amid Clinical and Financial Advancements - TipRanks
Plus Therapeutics: What’s Fueling the Surge? - timothysykes.com
PLUS THERAPEUTICS Inc. (PSTV) reports earnings - Quartz
What is HC Wainwright’s Estimate for PSTV FY2029 Earnings? - Defense World
HC Wainwright Has Lowered Expectations for Plus Therapeutics (NASDAQ:PSTV) Stock Price - Defense World
Plus Therapeutics (NASDAQ:PSTV) Earns “Buy” Rating from D. Boral Capital - Defense World
Plus Therapeutics outlines REYOBIQ expansion plans and CNSide launch timeline - MSN
Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer - AOL
Earnings call transcript: Plus Therapeutics’ Q4 2024 results highlight innovation - Investing.com Australia
H.C. Wainwright cuts Plus Therapeutics price target to $5.50 - Investing.com Australia
H.C. Wainwright cuts Plus Therapeutics price target to $5.50 By Investing.com - Investing.com Canada
Promising Outlook for Plus Therapeutics: Strategic Financial Moves and Innovative Assay Launch Justify Buy Rating - TipRanks
Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: S - GuruFocus
Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Plus Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Plus Therapeutics (PSTV) Reports Mixed FY Results, Revenue Surges - GuruFocus
Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Plus Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
PLUS THERAPEUTICS Earnings Results: $PSTV Reports Quarterly Earnings - Nasdaq
Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - The Manila Times
A Peek at Plus Therapeutics's Future Earnings - Benzinga
PLUS THERAPEUTICS Earnings Preview: Recent $PSTV Insider Trading, Hedge Fund Activity, and More - Nasdaq
Plus Therapeutics Introduces REYOBIQ - citybiz
Top Small Cap Stocks To Watch TodayMarch 20th - MarketBeat
PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug - TradingView
Thursday's Trending Pharma Stock Plus Therapeutics, Inc. (Nasdaq: PSTV) Gains 170% - Investorideas.com
Why Plus Therapeutics Inc. (PSTV) Surged On Thursday? - Insider Monkey
10 Micro-, Small-Cap Firms Dominate Thursday’s Gains - Insider Monkey
Plus Therapeutics Shares Jump After FDA Accepts Name of Lead Tumor Treatment Candidate - Marketscreener.com
FDA conditionally accepts new name for Plus Therapeutics drug By Investing.com - Investing.com South Africa
Plus Therapeutics announces FDA conditionally accepted name REYOBIQ - TipRanks
FDA conditionally accepts new name for Plus Therapeutics drug - Investing.com India
Why Plus Therapeutics Is Rising In Pre-market? - Nasdaq
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate - GlobeNewswire
Plus Therapeutics Scores FDA Recognition for REYOBIQ Cancer DrugMajor Milestone for CNS Treatment - StockTitan
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):